Answers are grounded in this paper and cite their sources.
Predicting steady-state volume of distribution (V ss ) is a key component of pharmacokinetic predictions and often guided using preclinical data. However, when bottom-up prediction from physiologically-based pharmacokinetic (PBPK) models and observed V ss misalign in preclinical species, or predicted V ss from different models varies significantly, no consensus exists for selecting models or preclinical species to improve the prediction. Through systematic analysis of V ss prediction across rat, dog, monkey, and human, using common methods, a practical strategy for predicting human V ss , with or without integration of preclinical PK information is warranted. In this analysis, we curated a dataset of 57 diverse compounds with measured physicochemical and protein binding data, together with observed V ss in these species. Using a bottom-up approach, prediction performance was consistent across species for each method. Although no method consistently outperformed others for all compound types and across species, M2 (Rodgers-Rowland method) performed marginally better for acids. Comparable compound-specific global tissue Kp scalars were needed to match observed V ss for both, human and preclinical species. Consequently, application of geometric mean values of preclinical Kp scalar to human V ss prediction improved accuracy. We propose a decision tree for human V ss prediction using PBPK methods with or without integrating preclinical PK information.
No takes yet. Share an insight, caveat, or question.
Ning et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: